Healthdirect Free Australian health advice you can count on.

Medical problem? Call 1800 022 222. If you need urgent medical help, call triple zero immediately

healthdirect Australia is a free service where you can talk to a nurse or doctor who can help you know what to do.

beginning of content

Dupixent TM

You should seek medical advice in relation to medicines and use only as directed by a healthcare professional. Always read the label. If symptoms persist see your healthcare professional.

Active ingredients: dupilumab

Brand name

(ARTG)

: DUPIXENT dupilumab (rch) 300 mg/2 mL solution for injection pre-filled syringe with needle shield

Download the Consumer Medicine Information Leaflet

Download consumer medicine information leaflet (pdf) from the Therapeutic Goods Administration (TGA) website

What this medicine is used for

(ARTG)

Dupixent is indicated for the following type 2 inflammatory diseases:,Atopic Dermatitis:,Adults and adolescents:,Dupixent is indicated for the treatment of moderate to severe atopic dermatitis in patients aged 12 years and older who are candidates for chronic systemic therapy. Dupixent is not intended for episodic use.,Children 6 months to 11 years of age:,Dupixent is indicated for the treatment of severe atopic dermatitis in patients aged 6 months to 11 years old who are candidates for chronic systemic therapy. Dupixent is not intended for episodic use.,Prurigo Nodularis:,Dupixent is indicated for the treatment of moderate-to-severe prurigo nodularis (PN) in adults who are candidates for systemic therapy.,Asthma:,Dupixent is indicated as add on maintenance treatment in patients aged 6 years and older with moderate to severe asthma with type 2 inflammation (elevated eosinophils or elevated FeNO) that is inadequately controlled despite therapy with other medicinal products for maintenance treatment (see Section 5.1 Pharmacodynamic Properties Clinical Trials).,Chronic rhinosinusitis with nasal polyposis (CRSwNP):,Dupixent is indicated as an add-on maintenance treatment in adult patients with inadequately controlled chronic rhinosinusitis with nasal polyposis (CRSwNP).Dupixent is indicated for the following type 2 inflammatory diseases:,Atopic Dermatitis,Adults and adolescents,Dupixent is indicated for the treatment of moderate to severe atopic dermatitis in patients aged 12 years and older who are candidates for chronic systemic therapy. Dupixent is not intended for episodic use.,Children 6 months to 11 years of age,Dupixent is indicated for the treatment of severe atopic dermatitis in patients aged 6 months to 11 years old who are candidates for chronic systemic therapy. Dupixent is not intended for episodic use.,Asthma,Dupixent is indicated as add on maintenance treatment in patients aged 6 years and older with moderate to severe asthma with type 2 inflammation (elevated eosinophils or elevated FeNO) that is inadequately controlled despite therapy with other medicinal products for maintenance treatment (see Section 5.1 Pharmacodynamic Properties Clinical Trials).,Chronic rhinosinusitis with nasal polyposis (CRSwNP),Dupixent is indicated as an add-on maintenance treatment in adult patients with inadequately controlled chronic rhinosinusitis with nasal polyposis (CRSwNP).

How to use this medicine

(ARTG)

This medicine contains one component only.

Component :

  • Injection, solution
  • Subcutaneous
  • Clear to slightly opalescent, colourless to pale yellow solution

Storage conditions

(ARTG)

  • Store at 2 to 8 degrees Celsius
  • Protect from Light
  • Do not Freeze
  • Protect from Heat
  • Refrigerate
  • Protect from direct sunlight
  • Store in Original Container
  • Do not Shake
  • Shelf lifetime is 36 Months.

Do I need a prescription ?

(ARTG)

These medicine packs are available from a pharmacist and requires a prescription. It is Schedule 4 : Prescription Only Medicine.

  • 2 pack
  • 2 - starter pack pack

Is this medicine subsidised ?

(PBS)

This medicine was verified as being available on the PBS (Pharmaceutical Benefits Scheme) on September, 1 2024. To learn more about this subsidy, visit the Pharmaceutical Benefits Scheme (PBS) website.

Pregnant or planning a pregnancy ?

(AHT)

For the active ingredient dupilumab

You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.

Reporting side effects

This medicine is under additional monitoring as it is new or being used in a different way. You can help identify new safety information by reporting any side effects you may get.

Back to top back to top

Need more information?

These trusted information partners have more on this topic.

Healthdirect 24hr 7 days a week hotline

24 hour health advice you can count on

1800 022 222

Government Accredited with over 140 information partners

We are a government-funded service, providing quality, approved health information and advice

Australian Government, health department logo ACT Government logo New South Wales government, health department logo Northen Territory Government logo Queensland Government logo Government of South Australia, health department logo Tasmanian government logo Victorian government logo Government of Western Australia, health department logo

Healthdirect Australia acknowledges the Traditional Owners of Country throughout Australia and their continuing connection to land, sea and community. We pay our respects to the Traditional Owners and to Elders both past and present.

© 2024 Healthdirect Australia Limited